Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
06 2020
Historique:
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 27 6 2020
Statut: ppublish

Résumé

We reviewed the diagnostic accuracy of SARS-CoV-2 serological tests. Random-effects models yielded a summary sensitivity of 82% for IgM, and 85% for IgG and total antibodies. For specificity, the pooled estimate were 98% for IgM and 99% for IgG and total antibodies. In populations with ≤ 5% of seroconverted individuals, unless the assays have perfect (i.e. 100%) specificity, the positive predictive value would be ≤ 88%. Serological tests should be used for prevalence surveys only in hard-hit areas.

Identifiants

pubmed: 32553061
doi: 10.2807/1560-7917.ES.2020.25.23.2000980
pmc: PMC7403641
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom

Références

Eur Respir J. 2020 May 19;:
pubmed: 32430429
Eur J Clin Microbiol Infect Dis. 2020 Jul 17;:
pubmed: 32681308
BMJ. 2020 Mar 23;368:m1165
pubmed: 32205334
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
J Clin Epidemiol. 2003 Nov;56(11):1129-35
pubmed: 14615004
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605

Auteurs

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Federica Bellerba (F)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Federica Corso (F)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Angélica Díaz-Basabe (A)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Gioacchino Natoli (G)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

John Paget (J)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.

Federica Facciotti (F)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Simone Pietro De Angelis (SP)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Sara Raimondi (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Domenico Palli (D)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Luca Mazzarella (L)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Pier Giuseppe Pelicci (PG)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Department of Hematology and Oncology, University of Milan, Milan, Italy.

Paolo Vineis (P)

MRC Centre for Environment and Health, School of Public Health, Imperial College, London, United Kingdom.

Sara Gandini (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH